Pure red cell aplasia: Association with large granular lymphocyte leukemia and the prognostic value of cytogenetic abnormalities

被引:102
作者
Lacy, MQ
Kurtin, PJ
Tefferi, A
机构
[1] MAYO CLIN & MAYO FDN, DIV HEMATOL & INTERNAL MED, ROCHESTER, MN 55905 USA
[2] MAYO CLIN & MAYO FDN, DIV PATHOL, ROCHESTER, MN 55905 USA
关键词
D O I
10.1182/blood.V87.7.3000.bloodjournal8773000
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
From 1980 through 1994, we identified 47 adult patients with acquired pure red cell aplasia (median age, 64 years; range, 22 to 84 years). Associated clinical disorders included T-cell large granular lymphocytic (LGL) leukemia, thymoma, chronic lymphocytic leukemia, and non-Hodgkin's lymphoma. Review of bone marrow findings in 40 patients showed absence of erythroid precursors in 14 patients and rare pronormoblasts in 26, None had morphologic evidence of myelodysplasia. T-cell receptor gene rearrangement studies with Southern blot technique in 14 patients showed clonal rearrangements in nine, Karyotypic analyses performed in 28 patients showed clonal abnormalities in four. Overall, 28 of 47 patients (60%) responded to immunosuppressive therapy, but none were the patients with cytogenetic abnormalities, There was a trend toward superior response to immunosuppressive agents in the patients with T-cell LGL leukemia. Cyclophosphamide, with or without corticosteroids, was the most useful treatment agent. Cyclosporine A was effective for refractory disease. Neither the presence of an associated clinical disorder nor the existence of detectable erythroid precursors affected overall survival. We conclude that (1) T-cell LGL leukemia is the disorder most commonly associated with pure red cell aplasia, (2) the presence of clonal cytogenetic abnormality predicts poor response to immunosuppressive therapy, and (3) oral cyclophosphamide and cyclosporine A are effective treatment regimens. (C) 1996 by The American Society of Hematology.
引用
收藏
页码:3000 / 3006
页数:7
相关论文
共 32 条
  • [1] PURE RED-CELL APLASIA - LYMPHOCYTE INHIBITION OF ERYTHROPOIESIS
    ABKOWITZ, JL
    KADIN, ME
    POWELL, JS
    ADAMSON, JW
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 1986, 63 (01) : 59 - 67
  • [2] PURE RED-CELL APLASIA - RESPONSE TO THERAPY WITH ANTI-THYMOCYTE GLOBULIN
    ABKOWITZ, JL
    POWELL, JS
    NAKAMURA, JM
    KADIN, ME
    ADAMSON, JW
    [J]. AMERICAN JOURNAL OF HEMATOLOGY, 1986, 23 (04) : 363 - 371
  • [3] PROPOSALS FOR THE CLASSIFICATION OF THE MYELODYSPLASTIC SYNDROMES
    BENNETT, JM
    CATOVSKY, D
    DANIEL, MT
    FLANDRIN, G
    GALTON, DAG
    GRALNICK, HR
    SULTAN, C
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 1982, 51 (02) : 189 - 199
  • [4] COMPLEMENT INDEPENDENT ERYTHROPOIETIC INHIBITOR ACTING ON PROGENITOR CELL IN REFRACTORY ANEMIA
    BROWMAN, GP
    FREEDMAN, MH
    BLAJCHMAN, MA
    MCBRIDE, JA
    [J]. AMERICAN JOURNAL OF MEDICINE, 1976, 61 (04) : 572 - 578
  • [5] RED-CELL HYPOPLASIA AND INCREASED BONE-MARROW RETICULIN IN SYSTEMIC LUPUS ERYTHEMATOSIS - REVERSAL WITH CORTICOSTEROID-THERAPY
    CAVALCANT, J
    SHADDUCK, RK
    WINKELSTEIN, A
    ZEIGLER, Z
    MENDELOW, H
    [J]. AMERICAN JOURNAL OF HEMATOLOGY, 1978, 5 (03) : 253 - 263
  • [6] CHARLES RJ, 1994, BLOOD, V84, pA216
  • [7] CLARK DA, 1984, BLOOD, V63, P277
  • [8] DESSYPRIS EN, 1991, SEMIN HEMATOL, V28, P275
  • [9] DESSYPRIS EN, 1980, BLOOD, V56, P421
  • [10] Dessypris EN, 1988, PURE RED CELL APLASI